Elmiron Class Action Lawsuit
The Dolman Law Group is presently representing individuals who used the prescription drug Elmiron, and have developed serious vision damage including maculopathy or macular degeneration. Elmiron is a drug manufactured by Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) to treat interstitial cystitis (also known as painful bladder syndrome) a chronic bladder condition. Please note that Janssen Pharmaceuticals did not add a warning label for Elmiron until 2020.
Clinical trials identified that an active ingredient in Elmiron known as pentosan polysulfate sodium (also known as PPS) is strongly linked to pigmentary maculopathy. Elmiron was prescribed to treat bladder pain but this drug has been shown to cause permanent eye injury.
All Elmiron lawsuits filed in Federal Court have been merged into a single MDL (Multidistrict litigation). In other words, all federal lawsuits have been consolidated before a single Judge in order to better coordinate discovery and increase consistency. Judge Brian Martinotti is overseeing all federal lawsuits in United States District Court, District of New Jersey.
If you've suffered harm that taking Elmiron has caused to your vision, even if you have not yet begun to suffer from failing eyesight, contact the experienced Elmiron lawsuit lawyers at Dolman Law Group for a free, confidential, no-obligation case consultation.
- Elmiron Class Action Lawsuit
- Elmiron Lawsuit Update
- Do I Qualify for an Elmiron Lawsuit?
- Elmiron Lawsuits: IC Drug Linked to Blindness and Eye Problems
- Does Elmiron Cause Blindness?
- What Is Elmiron?
- Elmiron Causes Vision Loss & Eye Problems
- The FDA Response to Link Between Elmiron and Eye Damage
- Elmiron Lawsuits Across the U.S.
- Elmiron Lawsuit Attorneys
- Elmiron Manufacturers Face Legal Liability
- Were You Harmed by Elmiron?
- Your Questions Answered About Elmiron Lawsuits
- Elmiron Lawsuit Settlement Amounts
- Call Our Experienced Dangerous Drug Injury Attorneys for Elmiron Victims
Elmiron Lawsuit Update
9/17/22 Elmiron Lawsuit Update
In the latest MDL statistics report tabulated by the Joint Panel on Multidistrict Litigation, there are presently 1774 lawsuits pending with Judge Martonotti in the Elmiron MDL. We are keeping a close eye on the Elmiron MDL as it is possible the defense will entertain or even commence discussion of a global settlement prior to the first bellwether trial scheduled for this coming January (January, 2023). The overall strength of all scientific evidence linking the use of this drug to macular degeneration and pigmentary maculopathy may force the defendants to resolve each and every Elmiron lawsuit within the MDL.
5/9/22 Elmiron Lawsuit Update
Judge Martonotti has selected three lawsuits to serve as bellwether trials for the Elmiron MDL. The first lawsuit picked by the plaintiffs was filed by Julia and Brian Manning of Georgia in May of 2021. The Manning lawsuit alleges plaintiff took Elmiron for six years and sustained injuries to both eyes. Further, they contend to have never received any warning and had no knowledge Elmiron posed any danger to their eyes. The case of Opal Faye Broussard was selected by the defense lawyers. She took Elmiron for several years and was diagnosed with macular degeneration along with vision loss. Finally, the third lawsuit chosen by both the defense and the Court was filed by Maria Windham of Louisiana. She used Elmiron for two years and alleges such use resulted in macular degeneration. The Wyndham case will serve as the first Elmiron bellwether trial and is scheduled to be tried in January, 2023.
Please note that the outcome of a bellwether trial is not binding on all plaintiffs in other Elmiron lawsuits in the MDL. However, it serves as a guide for all parties on how a jury may respond to specific evidence and arguments. In turn, the results from Elmiron bellwether trials may influence settlement of all claims.
January 7, 2022 Elmiron Lawsuit Update
An MDL has been established and will be overseen by Judge Brian Martinotti. There are presently 768 Elmiron lawsuits the make up this MDL. Elmiron litigation will slowly proceed forward as more lawsuits are added to the MDL and discovery proceeds forward. We anticipate many former Elmiron patients to come forward and commence litigation as this class action picks up steam.
Do I Qualify for an Elmiron Lawsuit?
In order to potentially qualify for an Elmiron lawsuit you must:
- have used Elmiron for a minimum of two years
- began experiencing vision propblems after January 1, 2010
- sought consultation or treatment for vision impairment
- diagnosed by a qualified physician with vision issues including macular degeneration, pigmentary maculopathy or retinal maculopathy following two years of Elmiron use.
- sustained changes to your vision inclding, difficulty reading, blurry vision, inability to adjust to darkness or vision loss following two years of Elmiron use
- diagnosed with vision issues while using Elmiron or within one year of when you stopped taking the medication
Taking Prescription Drug Elmiron for Bladder Pain Syndrome? Losing Your Eyesight? Call us.
If you developed vision problems, such as retinal maculopathy, after taking the prescription drug Elmiron, an experienced Elmiron lawsuit attorney can help. Currently, Elmiron patients are filing claims across the country against the manufacturers of Elmiron after suffering because of their defective drug. Our attorneys can help you file an Elmiron lawsuit and seek the justice you deserve. In fact, our Elmiron lawyers remain available for a free consultation or case review.
Elmiron Treats Interstitial Cystitis
For decades, the prescription drug Elmiron has been prescribed to treat interstitial cystitis (IC), a painful bladder condition that affects hundreds of thousands of Americans and for which there is currently no cure. In the United States, this condition affects between three to eight million women and one to four million men. Doctors have also prescribed Elmiron for off-label use to treat other chronically-painful diseases, including arthritis.
Recently, studies have shown that patients taking Elmiron report higher-than-normal rates of vision problems. Specifically, an unusually high number of patients prescribed Elmiron have developed a rare condition called retinal maculopathy, which can cause permanent blindness. The studies appear to show a link between taking Elmiron and these potentially severe vision problems. Sadly, the link gets stronger the more Elmiron the patient has taken.
People who have taken Elmiron by doctor's prescription for treatment of IC, Painful Bladder Syndrome (PBS), arthritis, or any other condition, and who have developed vision problems, may have legal rights to receive substantial compensation for the harm the drug appears likely to have caused to their eyesight.
The Dolman Law Group represent numerous individuals who have suffered injuries and health complications by taking dangerous medications. Contact our Elmiron Lawsuit Attorneys today to learn how taking Elmiron may have put your vision at risk, and what the law may entitle you to receive as compensation.
Elmiron Lawsuits: IC Drug Linked to Blindness and Eye Problems
Victims of Elmiron are currently filing lawsuits across the country. These mass tort lawsuits allege that the manufacturers of Elmiron, Johnson & Johnson and its subsidiary Janssen Pharmaceuticals, did not disclose the link between Elmiron and serious eye problems, including blindness to the public. As such, many patients with Interstitial Cystitis and other medical issues took Elmiron without knowing the potential risks. Now, they suffer from a wide range of eye problems that have severely impacted their vision.
In June 2020, Janssen Pharmaceuticals update the drug's product label to include a warning of vision problems. This label states that the drug can change pigments in the retina, causing a wide range of vision problems and eyesight changes. However, this warning came too late for many victims and their families.
Does Elmiron Cause Blindness?
Elmiron Side Effects
Recent studies have shown a significant link between the use of Elmiron and eye problems. In particular, it can cause significant eye damage and eyesight changes, including:
- Blurred vision
- Difficulty reading
- Eye pain
- Vision issues
- Vision loss and blindness
- Difficulty adjusting to the darkness
- Distorted vision
Studies also link the use of Elmiron to various eye diseases, such as:
- Macular degeneration
- Retinal maculopathy
- Pigmentary maculopathy
During clinical trials of 2,627 participants, patients suffered from numerous other side effects that can include but are not limited to:
- Headaches (4%)
- Hair loss (4%)
- Diarrhea (3%)
- Rash (3%)
- Abdominal pain (2%)
In an additional study of 128 patients, 6.3% of those taking the recommended dose of 300mg suffered from rectal hemorrhaging.
What Is Elmiron?
Pentosan polysulfate sodium, marketed exclusively under the brand name Elmiron, is a medication developed by Teva Pharmaceuticals and manufactured by Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson). The drug currently has no generic version; it is only available under its brand name, Elmiron.
Since 1996, Elmiron has been approved for use in the United States with a doctor's prescription to treat the painful bladder condition, Interstitial Cystitis, which is one of several conditions associated with PBS. Elmiron is a common therapy for IC, which is its only FDA-approved use. Over the past decade, however, doctors have also increasingly prescribed Elmiron for off-label use to treat the symptoms of certain inflammatory diseases (such as arthritis), as well as neurodegenerative and metabolic disorders.
On a chemical level, Elmiron resembles naturally-occurring glycosaminoglycan, a complex polysaccharide that plays an important biological role in human cellular regulation and repair. Researchers believe Elmiron acts by helping to maintain the health of cells in the lining of the bladder that are affected by IC.
Studies have also suggested that Elmiron may help to keep joint cartilage healthy, and may thereby offer effective treatment for painful, disease-related joint inflammation typical of arthritis. These studies have spurred the increase in doctors prescribing Elmiron for off-label use in treating arthritis.
Elmiron is not known to cure Interstitial Cystitis or any other condition. In fact, IC currently has no known cure. Instead, doctors prescribe Elmiron to treat their patients' chronic disease-related symptoms, such as the bladder pain and pressure commonly suffered by patients with IC and PBS, or the joint pain of osteoarthritis.
Researchers know Elmiron does not work in the same way as anti-inflammatory drugs. Elmiron is believed to create a protective barrier around the lining of the bladder and while it cannot cure interstitial cystitis, it does protect the lining from irritants that come from urine.
Because Elmiron is a therapy and not a cure, many patients take the drug continuously for years to treat their chronic symptoms. Researchers estimate that hundreds of thousands of patients have taken Elmiron by doctor's prescription for both FDA-approved and off-label uses since it came to market in 1996, many for a decade or more.
Elmiron Causes Vision Loss & Eye Problems
According to recent research, Elmiron appears to cause a toxic buildup in patients who take it for an extended period, leading to progressive (and potentially permanent) vision loss. This is the crux of Elmiron eye damage lawsuits. If you have taken or currently take Elmiron, speak to your doctor immediately about its potential risks to your eyesight.
In 2018, the Review of Ophthalmology published a small study of six patients at the Emory Eye Center in Atlanta, Georgia, who took Elmiron for Interstitial Cystitis and also complained of eyesight problems, such as blurred vision or trouble adjusting to the dark. The authors examined the patients using advanced diagnostic technology and reported finding a “striking pattern of abnormalities” on the patients' retinas (the back of the eye, also called the posterior pole) that had no known explanation.
The authors believed these abnormalities had caused the patients' vision problems and potentially resulted from previously unknown medication toxicity related to taking Elmiron.
In a follow-up study, the authors of the original findings screened four-years worth of patient records at their large metropolitan eye care center to identify all patients who had IC and who also had a documented history of taking Elmiron. In all, 80 patients fit that description. Of those, researchers found 14 who had the particular abnormalities in their retinas (called retinal maculopathy) that the authors had reported in the original study.
No other patient of the clinic had these abnormalities; they were only found in 14 of the 80 patients who had taken Elmiron. It also appeared that the length of time the patients had taken Emiron was the only risk factor for developing the abnormalities. The authors saw a slight uptick in the risk to patients for developing the abnormalities after five continuous years of taking Elmiron, and a significant increase in the risk of eye disease after seven years of taking the drug.
(More recent guidance from the Food and Drug Administration, discussed below, warns that vision problems could even start in patients who took the drug for less than three years.)
The authors concluded that their suspicions were likely correct: a toxic buildup from taking Elmiron appeared to cause potentially severe retinal disease and vision loss. A team of ophthalmologists in the Kaiser Permanente health care system surveyed its own patient files and found similar results.
The maculopathy (or disease of the center of the eye) that the Emory researchers identified can cause significant, lasting damage to patients' eyesight. People affected by it commonly complain of blurred vision, trouble adjusting to seeing in the dark, seeing spots, and perceiving straight lines as round or wavy. The risk gets progressively worse as the Elmiron-related toxicity rises in the patient's body. According to the American Academy of Ophthalmology, stopping the medication can mitigate the effects of the disease, but if left untreated or misdiagnosed, it can lead to permanent vision loss.
In their follow-up study, the Emory researchers warned of a particular danger of misdiagnosis of this condition. Its symptoms resemble those of at least two other common eye diseases—age-related macular degeneration (AMD) and pattern dystrophy—which means it may have gone misdiagnosed in patients for years.
Patients misdiagnosed with these lookalike conditions, especially AMD, may have continued taking Elmiron, which would only have made their vision problems worse and, tragically, could well have been chalked up to old age. Thousands of people, if not more, may have accepted losing their eyesight as an inevitable feature of getting old, when in fact continuing to take Elmiron may have actually caused their progressive blindness.
The FDA Response to Link Between Elmiron and Eye Damage
The U.S. Food and Drug Administration, or FDA, regulates the safety of the nation's food and medicine supply. The FDA's principal responsibilities include reviewing new drugs and new proposed uses of existing drugs, such as Elmiron. The FDA also issues public guidance about the safety of prescription and over-the-counter drugs.
The FDA works with the pharmaceutical industry and consumer advocates to monitor drug safety. When evidence of a potential danger related to a drug comes to the FDA's attention, the FDA will often investigate. If the FDA confirms a new danger related to a drug, it has the power to require the manufacturer to change the labeling of the drug to warn consumers about the danger or to pull the drug from the market altogether in a recall (as happened recently with Zantac).
Shortly after publication, the Emory researchers' findings related to Elmiron came to the FDA's attention. Although the FDA has not ordered a recall of Emiron, it recently required changes to the warnings that come with the medication to alert doctors and patients to the vision problems the Emory researchers found.
- Highlight the vision-loss related risks of prolonged use of Emiron, noting that cases of maculopathy have emerged in patients who used the drugs for less than three years.
- Advise patients to have a baseline retinal examination performed by an eye doctor before starting to take Elmiron, to repeat that examination after taking Elmiron for no more than six months, and to have periodic re-examinations performed after that.
- Note that vision changes resulting from taking Elmiron “may be irreversible” and may get worse “even after cessation of treatment.”
Time will tell if these warnings go far enough in protecting the public, or if the FDA will go further and recall Elmiron from the market altogether. However, just by requiring changes to the warnings packaged with Elmiron, the FDA has acknowledged the seriousness of the Emory researcher's findings.
In a nutshell, the FDA has announced that Elmiron may cause irreversible and progressive vision loss in patients who take it for an extended period of time. That would make Elmiron a truly dangerous drug.
Elmiron Lawsuits Across the U.S.
In May 2020, Tina Pisco filed an Elmiron lawsuit against Janssen Pharmaceuticals and Johnson & Johnson. In this lawsuit, Pisco states that she began taking Elmiron in 2012. It was later in 2018 that she noticed her vision had begun deteriorating at an alarming rate. She was then diagnosed in March of 2019 with an injury to the retina in both of her eyes. While Janssen has multiple side effects listed on their website including conjunctivitis, retinal hemorrhage, and optic neuritis, there was no mention at all of the permanent damage to vision.
There was another instance of a woman filing a lawsuit against Teva Pharmaceuticals USA and Janssen in March 2020. A Connecticut resident, Kimberly Pelzczar, stated in her lawsuit that ten years after she began taking Elmiron in 2005 her vision had also deteriorated in a rapid manner. After seeing medical professionals from 2015-2019 she was eventually diagnosed with permanent vision loss and retinal injury.
Our firm is investigating hundreds of Elmiron maculopathy claims. If you are suffering from an eye disorder and have taken Elmiron, contact us immediately to learn more about your rights and a potential claim against Janssen Pharmaceuticals, the manufacturer of Elmiron. The link between Elmiron and significant eye issues is very strong. Elmiron is causing similar symptoms to simply age-related macular degeneration. Call us today to file an Elmiron lawsuit.
Elmiron Lawsuit Attorneys
Dolman Law Group Accident Injury Lawyers, PA Hold Negligent Drug Companies Accountable
Dolman Law Group Accident Injury Lawyers, PA are affiliated law firms, based in Florida, that represent clients nationwide in product liability lawsuits. A significant portion of our law practice focuses on seeking compensation for individuals harmed by taking dangerous medication prescribed by their doctors to treat their various health conditions.
In addition to Elmiron, our firms are currently evaluating claims involving the following potentially dangerous medications:
- Zantac, the over-the-counter heartburn medication that was recently recalled due to concerns it contained dangerously high levels of N-Nitrosodimethylamine (NDMA), a known cancer-causing substance.
- Actos, a diabetes medication linked to bladder cancer.
- Fosamax, an osteoporosis medication known to cause bone death in the jaw.
- Humira, a medicine used to treat plaque psoriasis, ulcerative colitis, rheumatoid arthritis, and Chrone's disease that has been linked to cancer risk.
- Mirena, an implanted contraceptive for women linked to injuries involving perforation of the uterus and vaginal bleeding.
- Nuvaring, an implanted contraceptive linked to an increased risk of stroke and blood clots.
- Pradaxa, a blood thinner with dangerous side effects that include gastrointestinal bleeding, bleeding in the brain, and an increased risk of contracting the severe viral illness.
- Risperdal, an antipsychotic drug, often prescribed to children, known to dangerous side effects, including breast tissue growth in men.
- Talcum Powder, which has been linked to ovarian cancer.
- Zithromax, a powerful antibiotic that may increase risks for heart attack in some patients.
- Transvaginal Mesh, an implant once used to treat urinary incontinence in women that caused severe health complications.
Of course, no lawyer can guarantee that a client will recover compensation in a dangerous drug lawsuit. Every product liability matter has its own unique facts and circumstances that affect its outcome. However, clients of Dolman Law Group Accident Injury Lawyers, PA can rest assured that their lawyers have the base of knowledge, the legal sophistication, and the deep resources necessary to take on powerful drug companies whose products cause harm to innocent patients.
Elmiron Manufacturers Face Legal Liability
Elmiron has been on the market since 1996. In that time, potentially hundreds of thousands of patients have been exposed to it, many of whom have taken it continuously over years. It seems likely that many of them suffered vision loss caused by Elmiron, and may have continued taking Elmiron as it inflicted more and more damage on their eyes.
That potential tragedy leads experienced product liability lawyers like us to wonder just what the drug companies that developed and manufactured Elmiron and undoubtedly profited from its sales, knew about their product's risks to patient eyesight, and when they first knew it.
Drugmakers like Janssen Pharmaceuticals and Johnson & Johnson have legal (not to mention moral) obligations to warn the public about known product dangers. Unfortunately, time and again we have learned that the desire to continue profiting from a blockbuster drug like Elmiron can lead to drug companies turning a blind eye to, and even covering up, warning signs about the harm that their products cause.
Drug companies that put profits before patient safety expose themselves to legal liability.
Were You Harmed by Elmiron?
Lawsuits against Elmiron manufacturers present a unique set of challenges for the injured parties and their lawyers. What does this mean for people who have suffered vision loss, blindness, or eye damage from taking Elmiron?
Although only a few lawsuits have been filed involving vision loss from Elmiron, the initial indications suggest that patients may have a strong case to make against its original developer (Teva Pharmaceuticals) and its current manufacturer (Janssen Pharmaceuticals) for selling Elmiron with defective warnings. It appears possible that those companies either knew or should have known, that Elmiron causes retinal damage leading to vision loss. If that turns out true, then patients with (or at risk of) vision loss may have the right to receive substantial compensation for any harm done to them.
Fortunately, for now, at least one legal pitfall that dogs many dangerous drug cases will not interfere with patients seeking compensation for harm done by Elmiron: the drug has no generic version, so the legal limitations on suing for harm done by a generic drug will not apply. Similarly, any potential case against Elmiron has already received a significant boost from the FDA's recent acknowledgment of the need to change Elmiron's warning label to highlight its risk of causing progressive, and potentially irreparable, vision loss.
However, that does not mean that legal action for compensation due to vision loss associated with Elmiron will be a cakewalk. Far from it. Elmiron manufacturers will fight these cases aggressively because they threaten their reputations and profits. The laws and regulations that dictate what the companies, doctors, and even patients do are, at times, dizzyingly complex. Proving what Elmiron's developers and manufacturers knew or should have known about its catastrophic effects on patient vision will undoubtedly consume significant time, effort, and expense.
In other words, building and prosecuting a case for damages against Elmiron's manufacturers will require the talents of a knowledgeable, experienced, skilled legal team with deep resources and the chops to stand up against the largest corporations in and out of court. It's only a job for a firm stacked with talent, able to deploy top-notch negotiators and trial lawyers to meet anything a manufacturer's team of high-powered defense lawyers throws its way.
Dolman Law Group Accident Injury Lawyers, PA possess those credentials. We have a long track record of taking on powerful businesses and holding them accountable for the harm that they've caused. Our past successes put us in the privileged position of having a deep bench of talent, years of experience, and ample financial resources to dedicate to fighting on behalf of people injured by taking Elmiron.
Your Questions Answered About Elmiron Lawsuits
Dolman Law Group Accident Injury Lawyers, PA clients know that they can always get answers to their pressing questions about a legal matter we handle for them. As lawyers for people struggling with serious health challenges, we pride ourselves on the personalized attention we give to our clients to help them understand and manage the process of seeking compensation through legal action.
Below, we answer some frequently asked questions about Elmiron and your potential rights to seek compensation for damage the drug may have done to your eyesight. For answers to specific questions that aren't included here, contact us today.
Am I at risk of blindness from taking Elmiron?
Always consult a qualified doctor to evaluate risks to your own health from taking any medication.
According to current research, you may face risks of retinal damage and vision loss if you took Elmiron for a continuous period lasting months or more. The longer you take Elmiron, the higher the potential risk of harm to your eyesight, with risks rising significantly for any patient who has taken Elmiron continuously for several years. It is estimated that hundreds of thousands of patients may have had potentially toxic exposure to Elmiron that put their vision at risk.
According to current FDA guidance, anyone taking Elmiron, or who is about to begin taking Elmiron, should consult with an ophthalmologist (an eye doctor) immediately to have a baseline retinal examination performed, and should have follow-up retinal examinations performed periodically to monitor their eye health. Those patients should also consult with the doctor who prescribed Elmiron to them, to evaluate their health risks further, and to discuss potential alternative therapies for the condition the doctor prescribed Elmiron to treat.
I no longer take Elmiron, and my vision seems okay. Am I at risk?
According to current FDA guidance, yes, you may still have a risk to your eyesight. The progression of the retinal disease Elmiron appears to cause may continue even after you stop taking that drug. Consult immediately with an ophthalmologist and the doctor who prescribed Elmiron to you.
What is Maculopathy? Did Elmiron cause my Maculopathy?
The macula is the very center of the retina which is responsible for the fine details we are able to see, as well as a majority of our central vision. There are many different types of maculopathy that range from Cellophane Maculopathy, Malattia Leventinese, as well as age-related maculopathy. However, the specific form of maculopathy that Elmiron is causing is known as “pigmentary maculopathy of unknown etiology”. Even though it is a macular injury, the cause for its development is unknown.
Pigmentary maculopathy can present itself in a multitude of ways:
- Vitelliform deposits: yellowish, round lesions that form under the macula, resulting in loss of vision
- Retinal pigment epithelium atrophy: black, flat lesions that form as you age
- Parafoveal pigmented deposits: blood vessels that become abnormal which results in loss of vision
The medicine I take for my interstitial cystitis/painful bladder syndrome/arthritis is generic. Am I at risk?
At the moment, no generic version of Elmiron is available by prescription in the United States. If you are sure the medicine you take is generic, you live in the U.S., and you get the medicine from a U.S. pharmacy, then you are probably not at risk for the specific retinal disease associated with taking Elmiron.
Always consult your prescribing physician to make sure you know the names of the medicines you take and what your doctor prescribes them to treat.
Note: We cannot comment on whether you face a risk of vision loss generally. Only a qualified doctor can do that. We also cannot comment on your risks if you live in the U.S., but take medication purchased from a non-U.S. source. If you live in the U.S., buying pharmaceuticals from non-U.S. sources is both dangerous to your health and illegal.
What can I do to protect my rights after taking Elmiron?
You may have legal rights to recover substantial compensation for the harm Elmiron may have already caused and/or may cause in the future. Contact the experienced dangerous drug injury attorneys at Dolman Law Group Accident Injury Lawyers, PA today for a free, confidential, no-obligation case consultation. In a short meeting or conversation, we can assess your potential legal rights and give you an idea of whether you have a case to pursue money damages.
If I have an Elmiron lawsuit case, who is responsible?
That remains to be seen and will depend upon the specific facts of your history of taking Elmiron. However, as a general matter, we are aware of several lawsuits that have been filed against the developer of Elmiron, Teva Pharmaceuticals, and/or its current manufacturer, Janssen Pharmaceuticals. Those companies may face legal liability for harm to patients caused by Elmiron.
Depending upon the circumstances, individual patients harmed by Elmiron may also have claims against medical providers, pharmacies, or other individuals involved in prescribing and distributing Elmiron. Speak with us today to learn more.
Elmiron Lawsuit Settlement Amounts
How much is my Elmiron lawsuit worth?
That also remains to be seen and depends on your specific circumstances. We anticipate a grid like system wherein the most serious injuries (complete vision loss) are awarded the highest compensation and the rest of the injuries will be compensated based on the severity of such.
Further we expect the average Elmiron settlement to exceed $150,000.00, with some of the more severe injuries resolving for in excess of $250,000.00. However, it remains to be seen whether Janssen Pharmaceuticals and their defense lawyers will entertain settlement discussions prior to the first bellwether trial. It is possible for Elmiron litigation to extend into summer of 2023.
The Types of Compensation Sought in Elmiron Lawsuit Settlements
As a general matter, individuals harmed by using by an unreasonably dangerous, a defective product can seek compensation to help pay for the following:
- Current and future medical expenses associated with treating the condition caused by the dangerous product, such as hospitalizations, medical monitoring, surgery, medication, and doctor visits;
- Current and future non-medical expenses associated with living with or adapting to the condition caused by the dangerous product, such as the cost of learning to live with impaired vision or of hiring services to help out with daily activities that impaired vision limits a person's ability to do on their own;
- Current and future lost income resulting from missing time at work or becoming unable to work because of the health complications caused by the dangerous, defective product;
- Pain, suffering, and diminished quality of life caused by the injury or illness inflicted by the dangerous product; and
- In some cases, depending upon the facts of your case and the state in which you live, punitive (or exemplary) damages designed to punish the manufacturer of the dangerous product and to deter other manufacturers from putting the public at risk.
As you might imagine, the amounts of damages that fall into these categories will vary depending on the severity of the health complications a person suffers, the amount of dispute about who has liability for those injuries, and even the amount of money the manufacturers have on hand to pay damages. There is also no guarantee that a person will recover compensation through legal action against a manufacturer of a dangerous product. Lawsuits are inherently unpredictable. However, the science linking Elmiron to serious vision impairment and other eye related issues is strong. Thus, we believe Elmiron vision loss lawsuits will inevitably resolve for favorable amounts.
The most reliable way to build a strong case for compensation, however, is to hire experienced product liability lawyers like those at Dolman Law Group to represent you in your Elmiron eye damage lawsuit.
Is there an Elmiron class action? What is that, exactly?
A class action is a type of lawsuit in which a few people sue on behalf of a larger group of people who have suffered an identical type of harm through identical circumstances. Class actions make it possible to do justice on a broad scale for lots of injured people at once, saving time, effort, and expense.
In this case, Elmiron litigation has been organized into multi district litigation (MDL). An MDL is a little different than your typical class action lawsuit. In a class action, all claimants have common injuries. In an MDL, the injuries may vary by types and severity.
How long does it take to get Elmiron compensation?
That, too, depends on your circumstances. We have represented clients in product liability matters that lasted only a few months, but we have also had cases that take over a year to resolve. As a general proposition, dangerous drug liability cases tend to take longer than average, because of the complexity of the factual and legal issues typically involved.
Remember, too, that not all cases end in compensation. That is the goal, however, and the most reliable way to achieve that goal is to hire experienced, skilled, and resourceful legal counsel. Our law firm is representing many individuals in their Elmiron vision loss lawsuit.
How much does it cost to hire Dolman Law Group?
Dolman Law Group Accident Injury Lawyers, PA represent victims of product liability, which means clients come to us during some of the most difficult, and financially strained, times in their lives. For that reason, we will always speak with a potential client free-of-charge. It costs you nothing to contact us for a case evaluation.
We also represent virtually all of our clients on a contingency basis. This means that we work for a percentage of the money that we ultimately help recover on our clients' behalf. Our clients pay nothing to us up-front, which means we only get paid if our clients get paid, too.
We do this for two reasons.
- First, it enables anyone who has suffered an injury because of someone else's poor or dangerous decisions to seek our help, regardless of how much money those individuals have in their bank accounts when they walk through our doors.
- Second, it gives us the same goals as our clients: to obtain the maximum compensation as efficiently and effectively as possible.
Do not let money worries prevent you from speaking with an experienced lawyer about the risks you face from taking Elmiron and your potential rights to compensation.
I took Elmiron. What can Dolman Law Group Accident Injury Lawyers, PA Do for me?
If you contact us, then we can offer you a free, confidential, no-obligation case evaluation to help you determine whether you may have a legal right to pursue compensation. Do not wait to reach out. You may have limited time to protect your rights.
When, after a consultation, we agree to represent a client, our teams get to work developing a legal strategy to fit our client's needs and goals. The specific steps we take on a client's behalf vary widely from representation-to-representation.
However, generally speaking, in a dangerous drug injury matter like one involving a client who took Elmiron, we may:
- Investigate the circumstances of the client's history of taking the dangerous drug. In particular, our team may want to evaluate the strength of the evidence showing who prescribed the medication, the dosage, the condition it was prescribed to treat, and how long our client took it. We may also work directly with our client's existing medical team, or with medical experts, to evaluate the nature and extent of the injury our client has suffered from taking Elmiron or other dangerous drugs. Our goal in these investigations, typically, is to gather evidence to support our client's claim for damages, as well as to identify all parties who may face legal liability for the harm that our client has suffered.
- Negotiate with defense lawyers to seek a fair and appropriate resolution of our clients' claims. Most product liability matters get resolved through a settlement in which the injured person receives compensation, and in exchange releases the other party from further liability. Our teams have years of experience advocating for clients in high-stakes negotiations against powerful businesses and highly-paid defense attorneys. We know when to sit down at the negotiating table, and when to walk away, to achieve the best possible financial outcome for a client injured by a dangerous drug.
- Litigate in courtrooms nationwide when negotiation alone does not achieve the result that our Elmiron client needs and deserves. We are a team of aggressive, street-smart trial lawyers who have the sophistication to argue the most complex legal issues to a judge and to explain the most complicated issues to a jury in plain, clear language. When we say “We'll see you in court,” we mean it.
Call Our Experienced Dangerous Drug Injury Attorneys for Elmiron Victims
Did you take Elmiron with a doctor's prescription to treat a chronic condition, like interstitial cystitis, painful bladder syndrome, or arthritis? If so, then you may have suffered significant damage to your eyesight, which could get progressively worse. Speak with your doctor right away about your risks.
Then, contact the experienced Elmiron lawsuit lawyers at Dolman Law Group for a free, confidential, no-obligation case consultation. You may have the legal right to receive substantial financial compensation for the harm that taking Elmiron has caused to your vision, even if you have not yet begun to suffer from failing eyesight. Do not wait to learn about your right to compensation. Write to us online or call us at 833-552-7274 today to speak with an Elmiron attorney today for a free case review.
The Dolman Law Group works with local counsel in any jurisdiction outside Florida for the purpose of filing lawsuits in jurisdictions wherein we are not licensed. Thus, we will follow each State's ethical rules to ensure a local attorney is involved.